Propanc Biopharma, Inc. (PPCB) · Oct 29, 2026 · Delisting
Delisting notice — Delisting deadline November 2; appeal due October 30
Propanc Biopharma’s delisting notice puts its Nasdaq listing at risk just days after a 1-for-10 reverse split, with an appeal due October 30.
Propanc is a clinical-stage biotech preparing PRP, its lead cancer candidate, for a planned Phase 1b first-in-human study in up to 50 advanced solid-tumor patients, with first-patient screening targeted for February 2027. The company had just completed a 1-for-10 reverse split intended to restore Nasdaq compliance, so this filing lands as a setback to the financing and listing infrastructure supporting that clinical plan—not as a change to the drug program itself.
The immediate issue is a formal delisting threat. Nasdaq says Propanc failed the $1.00 minimum bid-price rule over the prior 30 consecutive business days, and the securities face delisting on November 2 unless the company appeals. 〔0〕
The procedural cushion is unusually thin. Because Propanc completed a reverse split within the prior year, Nasdaq says the company is not eligible for the normal 180-day compliance period. The company intends to appeal by October 30, and that appeal would stay delisting while the hearings panel considers the case; management also claims the bid-price deficiency was cured after the notice date, but that remains an assertion rather than a final Nasdaq determination. 〔1〕
The business is not interrupted today, but the capital-markets risk is material. The filing says operations and SEC reporting continue normally. 〔2〕 But delisting could reduce trading liquidity, shrink the investor base, restrict access to registered public offerings, and make equity compensation harder—meaning the notice threatens the funding mechanism around a cash-burning clinical program even if it does not delay the next trial step by itself.
Bottom line: This is a real listing and financing complication arriving immediately after the reverse split meant to solve it. The appeal and claimed cure keep delisting from being final, but the filing weakens confidence that Nasdaq compliance is fully secured.
Nasdaq appeal due October 30
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!